Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Clinical trial NCT05065970 · COMPLETED

Trial details

NCT number: NCT05065970
Sponsor: HI-Bio, A Biogen Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Immunoglobulin A (IgA) Nephropathy

Start date: 2021-08-31
Primary completion: 2023-02-06
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.